• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4 filed by Wright Robin

    5/12/23 4:07:27 PM ET
    $VACC
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $VACC alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
    1. Name and Address of Reporting Person*
    Wright Robin

    (Last) (First) (Middle)
    C/O VACCITECH PLC, UNIT 6-10,
    ZEUS BUILDING RUTHERFORD AVENUE, HARWELL

    (Street)
    DIDCOT X0 OX11 0DF

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Vaccitech plc [ VACC ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    05/11/2023
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Rule 10b5-1(c) Transaction Indication

      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Share Option (Right to Buy) $2.27 05/11/2023 A 19,197 (1) 05/11/2033 Ordinary Shares(2) 19,197 $0 19,197 D
    Explanation of Responses:
    1. The shares underlying this option shall vest in full on the earlier of (i) May 11, 2024 or (ii) the next annual meeting of shareholders of the Issuer, subject to the Reporting Person's continued service as a director through the applicable vesting date.
    2. The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
    /s/ William Enright, Attorney-in-Fact 05/12/2023
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $VACC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $VACC

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $VACC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Vaccitech Renames as Barinthus Biotherapeutics to Highlight Strategic Evolution into a T Cell Immunotherapy Company Targeting Chronic Infectious Diseases, Autoimmunity, and Cancer

    New Corporate Brand to be Unveiled at AASLD Liver Meeting® 2023 with Interim Data OXFORD, United Kingdom, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Barinthus Biotherapeutics plc (NASDAQ:BRNS), formerly Vaccitech plc (NASDAQ:VACC), a clinical-stage biopharmaceutical company developing novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity and cancer will present data from its Phase 2 Hepatitis B trials of VTP-300 at The American Association for the Study of Liver Diseases (AASLD) – The Liver Meeting® 2023, November 10-14 in Boston, MA. The company also announced today that it has changed its name to Barinthus Biotherapeu

    11/6/23 9:05:56 AM ET
    $VACC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Vaccitech to Host KOL Webinar on Seeking a Functional Cure for Chronic Hepatitis B on September 20, 2023

    OXFORD, United Kingdom, Sept. 13, 2023 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ:VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel T cell immunotherapeutics designed to harness the power of the immune system to treat chronic infectious diseases, cancer and autoimmunity, today announced it will host a Key Opinion Leader (KOL) Webinar to discuss the current treatment landscape for people living with chronic Hepatitis B Virus (HBV) infection and potential paths to a functional cure. Details are as follows: KOL Webinar: Seeking a Functional Cure for Chronic Hepatis BWednesday, September 20, 2023 between 14:00-15:00 ET.To register for the event

    9/13/23 8:00:00 AM ET
    $VACC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Vaccitech Reports Second Quarter 2023 Financial Results and Recent Corporate Developments

    OXFORD, United Kingdom, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ:VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel T cell immunotherapeutics designed to harness the power of the immune system to treat chronic infectious diseases, cancer and autoimmunity, today announced its financial results for the second quarter of 2023 and provided an overview of the Company's progress. "In the second quarter of 2023, Vaccitech achieved important clinical milestones for two of our lead programs in HPV and HBV, which included the final analysis for the Phase 1b/2a trial of VTP-300 presented at EASL," said Bill Enright, Vaccitech's Ch

    8/10/23 8:00:00 AM ET
    $VACC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VACC
    SEC Filings

    View All

    Vaccitech plc filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Barinthus Biotherapeutics plc. (0001828185) (Filer)

    1/5/24 4:15:12 PM ET
    $VACC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Vaccitech plc filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Barinthus Biotherapeutics plc. (0001828185) (Filer)

    12/22/23 4:01:12 PM ET
    $VACC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Vaccitech plc filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

    8-K - Barinthus Biotherapeutics plc. (0001828185) (Filer)

    11/9/23 4:32:00 PM ET
    $VACC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VACC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Pelletier Nadege

    4 - Barinthus Biotherapeutics plc. (0001828185) (Issuer)

    1/4/24 8:56:29 AM ET
    $VACC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Griffiths Graham

    4 - Barinthus Biotherapeutics plc. (0001828185) (Issuer)

    1/4/24 8:55:03 AM ET
    $VACC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Enright William

    4 - Barinthus Biotherapeutics plc. (0001828185) (Issuer)

    1/4/24 8:54:01 AM ET
    $VACC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VACC
    Financials

    Live finance-specific insights

    View All

    Vaccitech Reports Second Quarter 2023 Financial Results and Recent Corporate Developments

    OXFORD, United Kingdom, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ:VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel T cell immunotherapeutics designed to harness the power of the immune system to treat chronic infectious diseases, cancer and autoimmunity, today announced its financial results for the second quarter of 2023 and provided an overview of the Company's progress. "In the second quarter of 2023, Vaccitech achieved important clinical milestones for two of our lead programs in HPV and HBV, which included the final analysis for the Phase 1b/2a trial of VTP-300 presented at EASL," said Bill Enright, Vaccitech's Ch

    8/10/23 8:00:00 AM ET
    $VACC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Vaccitech Reports First Quarter 2023 Financial Results and Recent Corporate Developments

    OXFORD, United Kingdom, May 12, 2023 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ:VACC) (the Company, we or us), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious diseases, autoimmunity and cancer, today announced its financial results for the first quarter of 2023 and an overview of the Company's progress. "2023 has kicked off strongly for Vaccitech. In the first quarter, we strengthened our leadership team with the addition of Dr. Nadège Pelletier as our new Chief Scientific Officer, we generated positive final proof of concept data from one of o

    5/12/23 8:00:57 AM ET
    $VACC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Vaccitech Reports Full-Year 2022 Financial Results and an Update on Corporate Developments

    OXFORD, United Kingdom, March 24, 2023 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ:VACC) (the Company, we or us), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious diseases, autoimmunity and cancer, today announced its financial results for year end 2022 and an overview of the Company's progress. "2022 represented an extremely active year at Vaccitech in which the company continued to advance its exciting pipeline and strengthen the infrastructure necessary to support this and future growth. We announced the completion of enrollment of three clinical trials, and initiate

    3/24/23 8:06:29 AM ET
    $VACC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VACC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Vaccitech plc (Amendment)

    SC 13G/A - Barinthus Biotherapeutics plc. (0001828185) (Subject)

    2/13/24 10:17:50 AM ET
    $VACC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Vaccitech plc (Amendment)

    SC 13G/A - Vaccitech plc (0001828185) (Subject)

    1/20/23 1:35:01 PM ET
    $VACC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Vaccitech plc

    SC 13G - Vaccitech plc (0001828185) (Subject)

    10/7/22 4:36:37 PM ET
    $VACC
    Biotechnology: Pharmaceutical Preparations
    Health Care